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ABSTRACT 
The purpose of this study was to determine the pharmacokinetics and pulmonary disposition of 
minocycline in horses after a single intravenous (IV) and intragastric (IG) dose and after multiple 
IG doses.  The study hypotheses were that: minocycline would be present in the pulmonary 
epithelial lining fluid (PELF) and bronchoalveolar lavage (BAL) cells at concentrations 
exceeding those in plasma within 3 hours of IV or IG administration and achievable trough 
concentrations in the PELF and BAL cells after administration of IG minocycline would exceed 
a target concentration of 0.25 µg/mL. 
 Seven healthy adult horses from the resident teaching herd were used for the two part 
study.  For part one of the study, 6 horses received IV (2.2 mg/kg) or IG (4 mg/kg) minocycline 
in a randomized cross-over design. Plasma samples were collected prior to minocycline 
administration and 16 times within 36 hours. Bronchoalveolar lavages were performed 4 times 
within 24 hours for collection of PELF and BAL cells. For part two of the study, minocycline (4 
mg/kg) was administered IG every 12 hours for 5 doses to 6 horses. Plasma samples were 
collected before minocycline administration and 20 times within 96 hours. Bronchoalveolar 
lavages were performed 6 times within 72 hours for collection of PELF samples and BAL cells.   
In study 1, mean bioavailability of minocycline was calculated at 48% (range 35- 75%).  
In study 2, at steady state, mean + SD maximum concentration (Cmax) of minocycline in the 
plasma was 2.3 + 1.3 µg/mL and the terminal half-life was 11.8 + 0.5 hours. The median (25th 
and 75th percentiles) time to peak concentration (Tmax) was 1.3 (1.0 – 1.5) hours. The Cmax and 
Tmax of minocycline in the PELF were 10.5 + 12.8 µg/mL and 9.0 (5.5 – 12.0) hours, 
respectively. The Cmax and Tmax for BAL cells were 0.24 + 0.1 µg/mL and 6.0 (0.0 – 6.0) hours, 
respectively.  
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Oral bioavailability (48%) varied considerably among adult horses (35 – 75%). While 
minocycline was detected in the PELF and BAL cells within 3 hours of IV or IG drug 
administration, only concentrations in the PELF exceeded those in plasma. As predicted, PELF 
trough concentrations exceeded the target concentration of 0.25 µg/mL at all measured time 
points. Contrary to the study hypothesis, minocycline BAL cell concentrations at all measured 
time points were well below concentrations detected in plasma and PELF and the 0.25 µg/mL 
target concentration.  It was concluded that minocycline distributes into the PELF and BAL cells 
of adult horses.   
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INTRODUCTION 
Oral antimicrobials are often the mainstay for the treatment of pneumonia in adult horses 
due to their relative ease of administration and reduced financial burden to the owner. Broad-
spectrum antimicrobials available for oral administration to adult horses are limited to a few 
medications.  Doxycycline, while demonstrating good distribution to the lung and a broad-
spectrum of activity against many common bacterial respiratory pathogens including 
Streptococcus species (Bryant et al., 2000), underwent a pharmaceutical market shortage 
resulting in a marked increase in pricing.  Doxycycline experienced a 2000% increase in average 
retail price between 2012 and 2013 (AARP, 2016). Although the cost and availability of 
doxycycline has improved recently, there remains a clinical need for additional oral 
antimicrobial treatment options in adult horses.   
Minocycline, a tetracycline derivative, is a time-dependent bacteriostatic antimicrobial 
and as such its efficacy is influenced by the duration of time the antimicrobial concentration 
remains above the minimum inhibitory concentration (MIC). Minocycline is available off-label 
for oral administration to horses (Schnabel et al., 2012), and represents an attractive addition to 
the available antimicrobial options due to its broad-spectrum of antimicrobial activity and 
excellent tissue penetration (Agwuh and MacGowan, 2006; Bishburg and Bishburg, 2009), 
relatively low cost, and potential anti-inflammatory properties (Sapadin and Fleischmajer, 2006).  
Unfortunately, pharmacokinetic data on minocycline’s oral bioavailability and disposition into 
the lung is limited for adult horses. This information is important to more accurately predict the 
efficacy of minocycline in treating bacterial pneumonia in the adult horse. 
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CHAPTER 1: REVIEW OF THE LITERATURE 
Bacterial pneumonia in adult horses 
Respiratory disease in the adult horse can cause a significant financial loss to owners due 
to treatment costs and lost time when the horse is out of training and/or competition as well as 
possible loss due to death of some horses or diminished performance of others following 
recovery (Giguère, 2015).  According to veterinarians nationwide, infectious respiratory tract 
diseases in horses have been identified as one of the most common medical entities (Pusterla, 
Watson and Wilson, 2006).  Respiratory infections are the second most common reason for 
antimicrobial drug use in adult horses (Traub-Dargatz and Dargatz, 2009).  A common cause of 
respiratory disease in the adult horse is bacterial pneumonia.  Bacterial pneumonia in adult 
horses commonly occurs when bacterial pathogens from the nasal passages or oropharynx reach 
the lower airways and overwhelm the pulmonary defense system (Reuss and Giguère, 2015).  
The severity of bacterial pneumonia in adult horses can vary from mild-to-severe disease. 
Although many bacterial pathogens can be associated with pneumonia in the adult horse, 
Streptococcus equi subspecies zooepidemicus is the most common bacterial pathogen recovered 
from transtracheal washes (Reuss and Giguère, 2015; Foreman, Hungerford and Folz, 1992; 
Sweeney et al., 1991).   Streptococcus equi subspecies zooepidemicus is a commensal organism 
of the horse and is an opportunistic pathogen, which can cause respiratory compromise after viral 
pneumonia or other stressors such as transportation (McClure, Koenig and Hawkins, 2015; 
Oikawa et al., 1994; Foreman, Hungerford and Folz, 1992).  A study investigating bacterial 
isolates from equine infections, not just respiratory infections, found that Streptococcus equi 
subspecies zooepidemicus was the most common isolate from all submission sites (accounting 
for 22% of all isolates) and was the most common bacterial isolate from the respiratory tract 
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(Clark et al., 2008).  As a commensal organism, Streptococcus equi subspecies zooepidemicus 
infections can occur whenever the host’s defense systems are compromised.  Transportation is a 
known risk factor for causing pneumonia in adult horses. Bacterial contamination of the lower 
respiratory tract occurs as a routine consequence of transportation and is likely an important 
determinant in the development of transport-associated respiratory disease (Raidal, Bailey and 
Love, 1997).  A study investigating the contamination of the lower respiratory tract and 
peripheral blood neutrophil function, found a peripheral blood neutrophilia and a reduction in 
neutrophil phagocytic function for at least 36 hours after transportation (Raidal, Bailey and Love, 
1997).  In a study using the long distance transport model of equine respiratory disease, it was 
found that in horses with positive culture results, 94.5% were identified as Streptococcus equi 
subspecies zooepidemicus (Davis et al., 2006).  Adult horses commonly acquire bacterial 
pneumonia by aspiration of normal microorganisms of the upper respiratory tract (Giguère, 
2015).  Aspiration can occur secondary to esophageal obstruction or dysphagia in adult horses. 
Stress of transport also can affect the immune system and pulmonary defense system in the 
horse, which can result in the inability to effectively clear bacterial organisms especially 
Streptococcus equi subspecies zooepidemicus from the lower airway (Raidal, Bailey and Love, 
1997; Oikawa et al., 1995). 
Mixed bacterial infections can occur and may include both Gram positive and Gram 
negative bacteria as well as aerobic and anaerobic bacteria.  In one study, the most common 
anaerobes isolated were Bacteroides oralis and Bacteroides melaninogenicus and horses with 
anaerobic infections had a lower survival rate than horses with aerobic infections (Sweeney, 
Divers and Benson, 1985). 
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Pneumonia and lung abscesses may result in structural changes in the lung parenchyma 
and potentially affect future athletic performance, but research suggests that horses that recover 
without complications have a favorable prognosis for return to athletic performance (Lavoie, 
Fiset and Laverty, 1994; Ainsworth et al., 2000; Seltzer and Byars, 1996).  A study followed four 
adult horses that had lung abscesses and all returned to racing careers suggesting adult horses 
may perform successfully after appropriate treatment (Lavoie, Fiset and Laverty, 1994).   A 
study found that based upon racing performance in horses that resumed racing after appropriate 
treatment for pulmonary abscesses, the horses did not develop long-term residual lung damage 
and racing performance for horses that raced prior to the illness was not significantly different 
after the illness (Ainsworth et al., 2000).  Another study reviewing pleuropneumonia in 
Thoroughbred racehorses found that the prognosis for return to racing after recovery from 
uncomplicated pleuropneumonia appeared to be good (Seltzer and Byars, 1996).   These studies 
suggest that appropriate and timely treatment of pneumonia in the adult horse is important and 
that uncomplicated cases of pneumonia in the adult horse have a favorable prognosis of return to 
an athletic career. 
Pathophysiology of pneumonia  
Pneumonia is an infectious process that can occur when the normal respiratory defense 
mechanisms are impaired which allows invasion and overgrowth of bacteria in the lung 
parenchyma and leads to intra-alveolar exudate (Alcon, Fàbregas and Torres, 2005).  Many of 
the bacteria that cause pneumonia in the horse are commensal microorganisms of the upper 
respiratory tract and once these commensal microorganisms gain access to the lung parenchyma 
can cause inflammation and infection.  The development of pneumonia requires that the 
pathogen reach the alveoli by overwhelming the defense system either by virulence or 
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overpopulation of the pathogen (Alcon, Fàbregas and Torres, 2005).  Several factors can impede 
the normal respiratory defense mechanisms including underlying diseases, typically viral 
infections, use of sedatives, tracheal intubation, or antibiotics, all of which may alter the normal 
bacterial flora of the upper respiratory tract and lead to contamination of the lung parenchyma 
with bacterial pathogens (Alcon, Fàbregas and Torres, 2005).  Pleuropneumonia occurs when the 
infection from the pulmonary parenchyma extends to the visceral pleural and pleural space 
(Giguère, 2015).  The parietal pleural is highly innervated, and horses with pleuropneumonia 
often show signs of pleurodynia (pleural pain) (Giguère, 2015).  Pleuropneumonia has similar 
etiologies compared to bronchopneumonia, and long distance transport appears to be a major 
inciting cause (Giguère, 2015; Austin, Forman and Hungerford, 1995) Pneumonia causes a local 
inflammatory response in the lung and either the immune system resolves the inflammation or it 
leads to lung injury and bacteremia.  Figure 1 illustrates the systemic inflammatory response and 
the factors that modulate the response to pneumonia.  Microbial, microenvironmental and host 
factors are all involved in the extent and severity of the lung injury and bacteremia.  The lung 
injury and bacteremia lead to a systemic response which can lead to either resolution or sepsis.  
Sepsis is a negative feedback to the local inflammatory response and will continue the negative 
cascade of events. 
 The goal of the pulmonary defense system is to maintain the lower respiratory airways 
free of contaminating microorganisms that may initiate infection (Mason and Nelson, 2005).  
The status of the host’s immunity and the integrity of local pulmonary defense mechanisms are 
critical for effective antimicrobial therapy (Pennington, 1981).  The pulmonary defense system 
includes layers of anatomic barriers as well as the respiratory tract immune system that can 
eliminate microbial pathogens from the respiratory tract before the establishment of infection  
  
- 6 - 
 
 
 
Figure 1:  Systemic inflammatory response to pneumonia.  (From Deng JC and Standiford TJ.  
The systemic response to lung infection. Clinics in Chest Medicine. 2005; 26:1-9). 
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(Mason and Nelson, 2005).  The pulmonary defense mechanisms can be grouped into two 
categories; physical defense mechanisms and cellular defense mechanisms (Harada and Repine, 
1985).  The upper airways have many physical defense mechanisms to protect the lower airways 
from contamination including the nasal turbinates that filter out large particles. The sneeze and 
cough reflexes help eliminate particles from the upper and lower respiratory tracts.  The 
mucociliary escalator is an important defense mechanism that clears inhaled material.  Optimal 
mucus volume and good ciliary function are necessary to maintain an effective mucociliary 
escalator (Harada and Repine, 1985). Viral infections and general anesthetics can decrease 
mucociliary clearance (Harada and Repine, 1985).  Equine influenza and EHV-4 infections have 
demonstrated significant decrease in tracheal clearance rates for up to 30 days post infection 
(Willoughby et al., 1992). 
 Despite the physical defense mechanisms, many particulates and soluble material, such as 
microorganisms, make it down into the lower respiratory tract and are deposited in the alveoli.  
In response to this, cellular defense mechanisms are employed in an attempt to clear these 
pathogens.  Alveolar macrophages play a central role by participating in phagocytic and 
immunologic reactions (Harada and Repine, 1985).  The lower respiratory tract lining fluid 
includes many plasma proteins as well as secreted products from epithelial and inflammatory 
cells that have roles in the innate and adaptive immune systems (Mason and Nelson, 2005).  The 
immune system, especially cytokines, is important for protective innate responses to bacterial 
pneumonia.  Observations made in animal models with pneumonia have indicated that the 
inflammatory response with bacterial pneumonia is mostly compartmentalized to the lung (Deng 
and Standiford, 2005).   
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Pulmonary surfactant, which lines the alveolar surface, is composed of a complex of 
lipids and proteins (Chroneos, Sever-Chroneos and Shephard, 2010; Brogden, 1991).  Pulmonary 
surfactant is important in respiratory function by decreasing surface tension at the air-liquid 
interface which prevents alveolar collapse at the end of expiration. It is an integral component of 
the respiratory system’s innate immune system assisting in controlling inflammation and 
preventing bacterial pathogen infections in the distal lung (Chroneos, Sever-Chroneos and 
Shepard, 2010). During pneumonia, bacteria cause changes in pulmonary surfactant and these 
changes are mediated by bacteria acting directly on secreted surfactant or indirectly through 
pulmonary type II epithelial cells that produce surfactant (Brogden, 1991). Immunoglobulins, 
specifically IgA and IgG, are important to the pulmonary defense system with IgA as the most 
predominant immunoglobulin in upper respiratory secretions and IgG as the most predominant 
immunoglobulin in lower respiratory secretions (Mason and Nelson, 2004).   
Transportation and stress have been indicated as major causes of respiratory disease in 
the horse.  Horses that are allowed to lower their heads after transportation have been shown to 
rapidly clear increased inflammatory airway secretions and increased numbers of bacteria 
(Raidal, Bailey and Love, 1997).  Increases in cortisol concentrations, neutrophil counts and 
white blood cell counts were found in horses transported long distances compared to stabled 
horses.  These results provide insights into the immunological mechanisms associated with long-
term transport (Stull et al., 2004). 
Antimicrobial therapy 
Culture and sensitivity are important to diagnosing and treating bacterial pneumonia in 
the adult horse.  Broad-spectrum antimicrobials are often initiated while culture and sensitivity 
results are pending because of the potential of polymicrobial infections (Ruess and Giguère, 
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2015).  For suspected pneumonia cases, transtracheal washes are the preferred method for 
obtaining a sample for culture (Pusterla, Watson and Wilson, 2006; Reuss and Giguère, 2015).  
Organisms cultured from a transtracheal wash represent bacteria found in the distal trachea and 
lower airways (Pusterla, Watson and Wilson, 2006). Antimicrobial treatment for bacterial 
pneumonia, particularly when culture and sensitivity are unavailable should allow for broad-
spectrum coverage as well as good sensitivity towards common pathogens, such as 
Streptococcus equi subspecies zooepidemicus at the site of infection (Reuss and Giguère, 2015; 
Sweeney et al, 1991).  
 With culture and sensitivity, only in vitro efficacy is evaluated.  Bacterial susceptibility in 
vitro can be performed by disk diffusion, concentration-gradient agar diffusion, or broth dilution.  
Disk diffusion provides qualitative susceptibility data, whereas broth dilution and 
concentration/gradient tests express a quantitative minimum inhibitory concentration (MIC) 
(Giguère and Tessman, 2011).  The MIC is the lowest concentration of an antimicrobial agent 
which inhibits the growth of the targeted bacteria (Giguère and Tessman, 2011).  Susceptibility 
designations are established by comparing the antimicrobial’s MIC to clinical breakpoints 
instituted by the Clinical Laboratory Standards Institute.  Breakpoints are the concentration 
above and below which bacterial isolates are categorized as susceptible, intermediate, or resistant 
(Giguère and Tessman, 2011).  In vitro susceptibility of a specific pathogen does not guarantee 
clinical outcome because host factors such as age, immune status, site of the infection, 
distribution of the drug to the site of infection, severity of the infection and presence of mixed 
infection all contribute to the clinical response (Giguère and Tessman, 2011). 
Antimicrobial efficacy in vivo is affected by how well the medication is transported and 
diffused into the area of infection.  The activity of many antimicrobials is impaired by 
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unfavorable conditions that prevail at sites of infection (Rubinstein et al., 2000).  These 
conditions include pH, anaerobiasis, the presence of purulent material and dead bacteria 
(Rubinstein et al, 2000; Kӧnig, Simmen and Blaser, 1998).  Many factors influence antimicrobial 
penetration into bronchial secretions, including physiochemical characteristics of the 
antimicrobial as well as host factors like bronchial inflammation and injury (Pennington, 1981).  
In bronchopneumonia, the increased local inflammation may enhance permeability to 
antimicrobial molecules (Pennington, 1981). 
In the horse, antimicrobials are available for administration by many different routes 
including parenteral, oral, and aerosolized.  Parenteral administration includes intravenous or 
intramuscular injections.  Oral medications are administered by dosing syringe, nasogastric 
intubation, or as a top dressing on feed.  Aerosolized antimicrobials are often used as adjunctive 
therapy along with systemic (parenteral or oral) antimicrobials.  Aerosolized medications are 
most often administered via a nebulizer.  There are many options for equine nebulizers and 
inhalers on the market.  Aerosolized antimicrobials may achieve higher drug concentrations in 
the bronchial secretions and pulmonary epithelial lining fluid (PELF) than systemically 
administered antimicrobials (Reuss and Giguère, 2015; McKenzie and Murray, 2000).  A study 
with gentamicin compared concentrations in the serum and bronchoalveolar lavage (BAL) fluid 
after intravenous and aerosol administration found that the gentamicin concentration in BAL 
fluid of healthy horses was significantly greater after aerosol administration versus intravenous 
administration (McKenzie and Murray, 2000).  A major limitation of aerosolized gentamicin in 
the adult horse with bacterial pneumonia is the lack of activity gentamicin has against 
Streptococcus equi subspecies zooepidemicus (Giguère, 2015).  Aerosol therapy is an effective 
method of drug delivery to the respiratory tract (Duvivier et al., 1997). However, some potential 
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limitations to aerosol therapy include impaired delivery of the antimicrobial to poorly ventilated 
areas of the lungs, time-consuming administration, pulmonary tissue irritation, and 
contamination of the antimicrobial solution with bacteria (McKenzie and Murray, 2000).  
Antimicrobials commonly used for aerosol therapy are cephalosporins, penicillins, and 
aminoglycosides (Duvivier et al., 1997).  For severe pneumonia, especially in the early stages, 
intravenous antimicrobials are preferred because they can achieve higher plasma concentrations 
more quickly (Reuss and Giguère, 2015).   
Many horses with mild-to-moderate pneumonia are treated at the home stables rather than 
in a referral hospital setting.  Under these circumstances oral antimicrobials are favored because 
of the ease of administration, increased owner compliance, and the possibility for long-term 
treatment protocols (Winther, et al., 2010).  Bioavailability in orally-administered antimicrobials 
varies considerably with the drug and the fed or fasted state of the horse.  Food exerts 
complicated effects on the pharmacokinetics of a drug (Gu et al., 2007).  Decreased oral 
bioavailability in fed versus fasted horses has been reported for several drugs (Bouckaert et al., 
1994; Van Duijikere et al., 1995; Syker et al., 2015; Davis, Salmon and Papich, 2006) and may 
result from delayed gastric emptying or from a physical barrier to absorption with high roughage 
diets (Toothaker et al., 1980). In humans, food is not reported to effect tetracycline 
bioavailability (Agwuh and MacGovern, 2006; Bishburg and Bishburg, 2009).  The tetracyclines 
are strong chelating agents (Chopra and Roberts, 2001). Chelation activity inhibits the biological 
role of metal-dependent proteins, leading to disturbances in microbial cell homeostasis and 
resulting in blockage of microbial nutrition, growth, and development (Santos et al., 2012). In 
adult horses, maximum concentration (Cmax) decreased when doxycycline was administered as a 
top-dressing to grain (Davis, Salmon and Papich 2006) and feeding in dogs decreased Cmax for 
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oral minocycline (Hnot et al., 2015).  In horses provided ab libitum hay, the addition of grain did 
not result in decreased plasma minocycline concentrations (Schnabel et al., 2012).  Cost, horse 
temperament, and owner/caretaker ability often dictate the antimicrobial and route of 
administration in adult horses with bacterial pneumonia. 
Regarding oral antimicrobials there are only a few options for horses with bacterial 
pneumonia. Multiple antimicrobials may be administered especially in suspected polymicrobial 
or severe pulmonary infections.  Trimethoprim-sulfonamide, a potentiated sulfonamide, is very 
affordable in the adult horse and is administered orally twice a day. Trimethoprim-sulfonamide 
includes two separate antimicrobials: Trimethoprim and sulfamethoxazole or sulfadiazine.  
When combined, these antimicrobials function synergistically and result in bactericidal activity 
(McClure, Koenig and Hawkins, 2015). Sulfonamides inhibit folate synthesis by inhibiting 
synthesis of bacterial DNA and trimethoprim inhibits folate synthesis by binding to dihydrofolate 
reductase and inhibiting the reduction of dihydrofolic acid to tetrahydrofolic acid (McClure, 
Koenig and Hawkins, 2015).  However, trimethoprim-sulfonamide is generally not effective in 
vivo against Streptococcus equi subspecies zooepidemicus, the most common cause of bacterial 
pneumonia in the adult horse (Reuss and Giguère, 2015).  Furthermore, in horses, potentiated 
sulfonamides do not achieve equal concentrations of both drugs in the lung (Winther et al., 
2010a) and their clinical utility for treating lower respiratory infections is limited due to their 
poor in vivo activity against Streptococcus equi subspecies zooepidemicus (Winther et al., 2010a; 
Ensink, Smit and van Duijkeren, 2003; Ensink, Bosch and van Duijkeren, 2005; McClure, 
Koening and Hawkins, 2015).   
Chloramphenicol is a broad-spectrum antimicrobial with good activity against aerobic 
and anaerobic bacteria as well as both Gram negative and Gram positive organisms (Kasten, 
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1999).  The mechanism of action for chloramphenicol is by inhibiting protein synthesis by 
binding to the 50S subunit of the 70S ribosome and preventing the bonding between amino acids 
and peptides (Smilack, Wilson and Cockerill, 1991; Kasten, 1999).  Chloramphenicol is 
generally bacteriostatic, but has demonstrated bactericidal activity against meningitis-causing 
organisms (Smilack, Wilson and Cockerill, 1991; Kasten, 1999; Feder, Osier and Maderazo, 
1981).  Chloramphenicol distributes well in body fluids and reaches high concentrations in the 
brain and cerebral spinal fluid (Kasten, 1999; Smilack, Wilson and Cockerill, 1991).  In humans, 
concerns of toxicity leading to reversible bone marrow depression and ‘grey syndrome’ in 
infants has decreased the popularity of the drug (Smilack, Wilson and Cockerill, 1991; Kasten, 
1999; Feder, Osier and Maderazo, 1981).  In the adult horse, chloramphenicol is expensive, is 
administered four times per day, and can be associated with human health risks (Giguère, 2015; 
Kasten, 1999).  The human health risk for owners handling the drug is uncommon but can result 
in irreversible aplastic anemia in certain people that come into contact with the antimicrobial 
(Feder, Osier and Maderazo, 1981).  Owners must be warned of the risk and advised to wear 
gloves when handling the medication.   
Enrofloxacin, a fluoroquinolone, can be administered intravenously as well as orally to 
adult horses.  Enrofloxacin has bactericidal activity and primarily targets Gram negative bacteria 
(Davis et al., 2006). The mechanism of action of enrofloxacin involves inhibition of bacterial 
DNA gyrase activity and interference with bacterial DNA packing, replication, and transcription 
(Magdesiam KG, 2015). In the horse, enrofloxacin has demonstrated good activity against 
Enterobacteriacaea, reliable penetration in tissue and phagocytic cells as well as respectable 
activity in purulent material (Reuss & Giguère, 2015).  Enrofloxacin has poor activity against 
Streptococcus species as well as anaerobes and therefore its use as sole therapy is not 
  
- 14 - 
 
recommended in horses with bacterial pneumonia without documentation of the culture and 
sensitivity of the causative agent (Reuss and Giguère, 2015).  A study that looked at the use of 
enrofloxacin in a long-distance transport model of equine respiratory disease concluded that solo 
therapy with enrofloxacin may not be appropriate for the treatment of Gram positive pathogens, 
specifically Streptococcus equi subspecies zooepidemicus, in equine respiratory disease (Davis et 
al., 2006a).  Enrofloxacin is administered once daily and is moderately expensive to treat an adult 
horse.  
Metronidazole is a synthetic drug and is effective against anaerobic organisms as well as 
certain protozoa and parasites (Kasten, 1999; Smilack, Wilson and Cockerill, 1991).  
Metronidazole is one of the most useful antimicrobials for the treatment of serious anaerobic and 
polymicrobial infections (Kasten, 1999).  The mechanism of action is damage to the bacterial 
DNA which results in cell death (Kasten, 1999; Smilack, Wilson and Cockerill, 1991).  
Metronidazole can be administered both orally and rectally to the horse. Clinical failures with 
metronidazole can occur when it is used alone to treat anaerobic pleuropulmonary infections 
probably because of the polymicrobial nature of these infections (Kasten, 1999). 
 Doxycycline, a second-generation tetracycline, has been used as an oral antimicrobial to 
treat bacterial pneumonia in the horse.  Doxycycline is not administered intravenously in horses 
as it can cause collapse and sudden death, apparently secondary to cardiovascular effects (Riond 
et al., 1992).  A study found that doxycycline at a dosage of 20 mg/kg every 24 hours orally 
would result in drug concentrations adequate for killing intracellular bacteria and bacteria with 
an MIC<0.25 ug/mL (Davis, Salmon and Papich, 2006). Winter et al. (2010) examined the 
disposition of doxycycline in the PELF of horses and demonstrated that clinically relevant 
doxycycline concentrations were possible to achieve in PELF after intragastric administration.   
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Doxycycline administered intragastrically over multiple days to foals at a dose of 10 mg/kg 
every 12 hours corresponded to serum, PELF and BAL cell concentrations that were maintained 
above MIC for most bacterial pathogens commonly isolated from the lower respiratory tract of 
foals with pneumonia (Womble, Giguère and Lee, 2007).  Under current recommendations, 
doxycycline is administered orally twice daily. In the past this drug was very affordable, but due 
to a pharmaceutical shortage, price increases over the past few years have made treating an adult 
horse with doxycycline prohibitively expensive.   
 Minocycline, also a second-generation tetracycline, has become more popular in 
veterinary medicine, especially with the increase in cost of doxycycline.  Few studies have been 
performed in horses with minocycline and even fewer have examined the pulmonary 
pharmacokinetics.  Adult horses achieved minocycline concentrations in synovial and 
cerebrospinal fluid that were adequate to treat infections caused by susceptible (MIC<0.25ug/ml) 
bacterial organisms after intragastric administration of 5 doses of minocycline (4 mg/kg) 
(Schnabel et al., 2012).   In a separate study, the administration of a single intravenous dose of 
minocycline (2.2 mg/kg) resulted in minocycline concentrations in lung tissue homogenates that 
exceeded plasma concentrations at two hours post drug administration (Nagata et al., 2010).  A 
recent publication demonstrated that in healthy 6 to 9 week-old foals, minocycline 
concentrations in PELF were significantly higher when compared to serum or synovial fluid 
concentrations (Giguère et al., 2016).  The same study also calculated a bioavailability of 57% in 
foals and 32% in adult horses (Giguère et al., 2016). 
Tetracyclines 
Tetracyclines are broad-spectrum antimicrobials with activity against both Gram positive 
and Gram negative bacteria as well as intracellular chlamydiae, mycoplasmas and rickettsiae 
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organisms (Roberts, 2003; Jonas and Cunha, 1982).  Tetracyclines have been used in human 
medicine since the 1950s for treatment of a wide variety of bacterial infections.   For humans, 
tetracyclines have been prescribed for prophylaxis and treatment of community-acquired 
infections especially respiratory infections (Roberts, 2003). 
The mode of action of tetracyclines is through reversibly inhibiting bacterial protein 
synthesis by binding the ribosomal complex which prevents the association of aminoacyl-tRNA 
and messenger RNA within the bacterial ribosome (Roberts, 2003; Chopra and Roberts, 2001; 
Carris et al., 2015).  The tetracycline molecules bind reversibly with the prokaryotic 30S of the 
bacterial ribosomal subunit, inhibiting protein synthesis (Roberts, 2003; Carris et al., 2015).   
Tetracyclines also have non-antimicrobial effects, which are beneficial in disease states 
including anti-inflammatory properties, immunosuppression, inhibition of lipase and collagenase 
activity, and increased wound healing (Roberts, 2003).  Tetracyclines reduce the concentration of 
a large variety of inflammatory mediators such as tumor necrosis factor, interleukin-1, matrix 
metalloproteinases (MMP), and reactive oxygen intermediates (Nieman and Zerler, 2001).   One 
of the best characterized non-antimicrobial properties of the tetracyclines is their ability to inhibit 
members of the MMP family of endopeptidases.  The MMPs are zinc-dependent proteases that 
are involved in many pathophysiological processes including inflammation and tissue invasion 
(Nieman and Zerler, 2001; Griffin et al., 2010).  Horses with recurrent airway obstruction (RAO) 
have increased concentrations of MMP-8 and MMP-13 found in tracheal epithelial fluid 
compared to healthy horses (Raulo, Sorsa and Maisi, 2006).  An in vitro study with RAO horses 
found decreased concentrations of MMP-8 and MMP-13 after administration of chemically 
modified tetracyclines (Raulo, Sorsa and Maisi, 2006).  Another non-antimicrobial property of 
tetracyclines is their ability to scavenge reactive oxygen species (ROS) (Griffin et al, 2010; 
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Nieman and Zerler, 2001).  Inflammatory processes produce excess ROS which can lead to 
oxidative destruction to cells and tissues (Griffin et al., 2010). 
Minocycline is a second-generation tetracycline derivative and first appeared in scientific 
research in 1967 (Jonas and Cunha, 1982).  Minocycline has the same basic four-ring structures 
as the other tetracyclines, but a substitution of a dimethyl amino group at C7 and the removal of 
a functional group at C6 allows for the unique chemical characteristics of minocycline (Jonas 
and Cunha, 1982).  Compared to other tetracyclines, minocycline has superior lipophilic 
properties.  These lipophilic properties are therapeutically significant as they result in increased 
penetration of tissues and enhanced gastrointestinal absorption (Jonas and Cunha, 1982).  
Minocycline also exerts anti-inflammatory properties that are completely separate from its 
antimicrobial actions (Yrӓnheikki et al., 1999).  It has been reported in animals that the 
beneficial effect of minocycline is associated with reduction of COX-2 expression and 
prostaglandin production (Yrӓnheikki et al., 1999).  Compared to doxycycline, minocycline has 
lower protein binding.  Minocycline has reportedly had protein binding ranging from 68.1 + 
2.6% (Nagata et al., 2010) and 75-85% (Jonas & Cunha, 1982).  Doxcycline was found to be less 
highly protein bound in horses than other species, with a mean percentage of 81.76 + 2.43% (free 
drug 18.24%) (Davis, Salmon and Papich, 2006). 
Pharmacokinetic principles 
Pharmacokinetic/pharmacodynamic (PK/PD) studies currently play a crucial role in drug 
development, drug evaluation, and in establishing effective drug dosage regimens (Riviere, 2011; 
Derendorf and Meibohm, 1999). Pharmacokinetic/pharmacodynamic modeling links dose-
concentration relationships (PK) and concentration-effect relationships (PD), which facilitate the 
description and prediction of the time course of the drug effects resulting from a certain dosing 
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regimen (Derendorf and Meibohm, 1999).  Presently, the most commonly used PK/PD 
approaches for antimicrobial drugs depend on plasma concentrations as the PK input and MIC as 
the PD input (Giguère and Tessman, 2011).  Minimum inhibitory concentration (MIC) is the 
lowest drug concentration that inhibits bacterial growth and minimum bactericidal concentration 
(MBC) is the lowest drug concentration that kills 99.9% of bacteria (Dowling and Davis, 2015).  
Minimum inhibitory concentrations are used to determine the antimicrobial dosage with the goal 
of achieving plasma and tissue concentrations above the in vitro MIC for the bacterial pathogen 
(Dowling and Davis, 2015). 
Antimicrobials are commonly classified as bactericidal or bacteriostatic based on the 
MBC-to-MIC ratio.  If the ratio is small, the antimicrobial is considered bactericidal, and drug 
concentrations are able to kill 99.9% of the organisms (Dowling and Davis, 2015).  If the ratio is 
large, the antimicrobial is considered bacteriostatic.  The distinction between bactericidal and 
bacteriostatic is not precise and depends on the antimicrobial concentration at the site of 
infection and the bacterial organisms involved (Dowling and Davis, 2015). 
Dosage regimen is also calculated based on the PK and PD relationship between the 
antimicrobial and the bacterial pathogen. For PK parameters the area under the plasma 
concentration versus time curve for 24 hours is calculated and maximum plasma concentration 
(Cmax) and the time the antimicrobial concentration exceeds a define PD threshold is time (T) 
(Dowling and Davis, 2015).  Minimum inhibitory concentration is used commonly as the PD 
parameter.  To relate PK and PD parameters to clinical efficacy, the action of the antimicrobial 
needs to be defined as concentration or time dependent.  Concentration-dependent antimicrobials 
include aminoglycosides, fluoroquinolones and metronidazole. They exert concentration-
dependent killing characteristics where bactericidal activity increases as plasma drug 
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concentrations increase above the MIC for that pathogen (Giguère and Tessman, 2011).  Time- 
dependent antimicrobials used in horses include β-lactams, tetracyclines, macrolides, potentiated 
sulfonamides, and chloramphenicol. They are effective based on the length of time that the 
pathogens are exposed to concentrations of the drugs above the MIC of the pathogen (Giguère 
and Tessman, 2011).   
Only free tissue concentrations of the antimicrobial at the target site are responsible for 
the therapeutic effects (Liu, Muller and Derendorf, 2002).  Many antimicrobials properties, 
including protein binding, lipid solubility, and volume of distribution, affect how well an 
antimicrobial may reach the infected tissue. Plasma-protein binding influences a drug’s ability to 
penetrate tissue as only the unbound fraction is available to cross biologic membranes.  Thus, the 
higher the plasma-protein binding of the antimicrobial, the lower the ability to penetrate into the 
tissue (Liu, Muller and Derendorf, 2002).  Furthermore, only the free tissue concentration of an 
antimicrobial at the site of infection, typically lower than the plasma concentration, is 
responsible for the therapeutic effects of the drug (Liu, Muller and Derendorf, 2002). In the lung, 
binding to protein within the PELF can further influence the amount of active drug that is 
available (Kiem and Schentag, 2008) particularly during inflammatory conditions resulting in 
changes in protein within the PELF. Protein concentrations in PELF have been reported to be 
much lower than in the plasma in healthy humans and in humans with pulmonary disease 
(Rennard et al., 1986). In healthy adult horses, the percentage of protein binding of doxycycline 
in the PELF was much lower than protein binding in the plasma (Rodvold, George and Yoo, 
2011). Lipid-soluble antimicrobials penetrate non-fenestrated capillary beds better than 
antimicrobials that are more water soluble (Levison and Levison, 2007).  Examples of lipid-
soluble antimicrobials are metronidazole and rifampin and examples of more water-soluble and 
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less lipid-soluble antimicrobials are aminoglycosides, glycopeptides, and β-lactams (Levison and 
Levison, 2009).  Non-ionized antimicrobials tend to be more lipid soluble and can more easily 
diffuse across cell membranes.  In contrast, ionized antimicrobials are less able to diffuse across 
lipid membranes because of low lipid solubility (Buxton and Benet, 2011; Levison and Levison, 
2009).   
The volume of distribution represents the relationship between the total amount of the 
antimicrobial in the body and the concentration of the antimicrobial measured in the plasma 
(Buxton and Benet, 2011). The volume of distribution of an antimicrobial reflects the extent to 
which the drug distributes from the plasma to the extravascular tissues (Buxton and Benet, 
2011).  Many host and antimicrobial properties can influence the volume of distribution 
including plasma and tissue volumes, drug protein binding, accumulation of drug in poorly 
perfused tissue as well as age, body mass, and disease state (Buxton and Benet, 2011).   
   Pharmacokinetic models are used to predict a drug’s behavior in the body.  In order to 
apply mathematical principles, a model of the body must be selected (Spruill et al., 2014).  The 
models are used to predict the time course of drug concentration throughout the body (Spruill et 
al., 2014). Pharmacokinetic data analysis utilizes either a model fitting using non-linear 
regression analysis or non-compartmental analysis (Reisfeld and Mayeno, 2012).  
Compartmental models are often used for describing concentration-time curves of drug plasma 
concentrations following drug administration.  The compartmental model describes how long the 
drug remains available in the body and is used as a guide for determining dosage regimens, 
delivery of the drug, and expectations of its effect (Reisfeld and Mayeno, 2012).  Non-
compartmental modeling requires fewer assumptions than model-based approaches and describes 
the drugs clearance, elimination half-life, and Cmax (Reisfeld and Mayeno, 2012).    
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Pulmonary pharmacokinetics 
Designing an optimal dosage regimen for the treatment of lower airway infections in the 
horse requires knowledge on the distribution of the antimicrobial in the equine lung.  Several 
studies in the horse and other species have demonstrated that the pharmacokinetics of 
antimicrobial drugs in the lung cannot be predicted by the plasma concentrations (Winther, 2012; 
Giguère and Tessman, 2011; Kiem and Schentag, 2008).  Most dosage regimens for equine 
antimicrobials have been established from pharmacokinetic studies, based on plasma 
concentrations over time and correlated with bacterial MICs (Winther, 2012).  Using plasma 
concentrations frequently overestimates the target site concentrations and clinical efficacy (Liu, 
Mϋller and Derendorf, 2002).  For pulmonary infections, antimicrobial concentrations in the 
PELF for extracellular pathogens and in alveolar macrophages cells for intracellular pathogen are 
thought to reflect antimicrobial activity in pneumonia (Kiem and Schentag, 2007).  Figure 2 
illustrates the blood-alveolar barrier which is composed of the capillary wall and alveolar wall, 
both of which are separated by the fluid filled interstitial space (Kiem and Schentag, 2007).  The 
antimicrobial concentration measured in the PELF represents the proportion which diffuses 
readily across the alveolar capillary wall, the interstitial fluid, and the alveolar epithelial cells 
(Kiem and Schentag, 2007; Giguère and Tessman, 2011).  There are several factors that affect 
the entry of an antimicrobial into the PELF including protein binding and lipophilicity.  Only the 
free, unbound portion of the antimicrobial is considered microbiologically active and able to 
equilibrate between the serum and interstitial fluid, suggesting that highly protein-bound 
antimicrobials will have a lower concentration in the PELF (Kiem and Schentag, 2007; Giguère 
and Tessman, 2011). In a recent study, the properties of protein binding and lipophilicity, which 
are often cited as determinants of drug penetration into the PELF, did not have an influence on  
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Figure 2: Schematic diagram of the blood-alveolar antibiotic barrier. The blood-alveolar barrier 
is composed of two membranes, the capillary wall and alveolar wall, which are separated by a 
fluid-filled interstitial space. Antibiotics need to diffuse across the alveolar capillary wall, the 
interstitial fluid, and the alveolar epithelial cells to reach ELF. Cells can carry antibiotics to the 
ELF also. Kiem S, Schentag JJ. Antimicrobial Agents Chemotherapy. 2008; 52:24-36. 
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the penetration of the antimicrobials administered to the calves (Foster, Martin and Papich, 
2016). 
With inflammation and infection, the pulmonary membrane thickness may be increased, 
leading to potential diffusion impairments of antimicrobials diffusing into the PELF from the 
vascular space.  However, in bronchopneumonia increased local inflammation may enhance 
permeability to antimicrobial molecules (Pennington, 1981).  Only the free tissue concentrations 
of antimicrobials at the target site are responsible for the therapeutic effect (Liu, Mϋller and 
Derendorf, 2002).   The more lipophilic the antimicrobial, the easier it can diffuse across 
membranes and enter the PELF (Winther, 2012).  Lipophilic antimicrobials like minocycline 
enter most tissues of the body, penetrate cellular barriers, and then reach the infection foci 
(Baggot and Prescott, 1987).  Because molecular weight for most antimicrobials is low, passive 
diffusion occurs across the membranes down the concentration gradient into the PELF (Winther, 
2012).  Passive diffusion is also influenced by the surface area and the membrane thickness.   
 There are a few different methods to measure antimicrobial concentration in the lung of 
the horse.  Sampling methods for the equine lung include homogenized lung tissue, nasal and 
bronchial secretions, microdialysis, absorbent disc/cotton swab, and bronchoalveolar lavage.  
 Tissue homogenates can often be misleading for pharmacokinetic purposes because the 
homogenate represents a mixture of all tissue compartments: intracellular, extracellular, blood, 
and interstitial drug concentrations (Winther, 2012; Giguère and Tessman, 2011). They also do 
not provide any information about active drug.  The antimicrobial concentration can often be 
underestimated for drugs that equilibrate completely within the extracellular space and become 
diluted by cells and blood (Giguère and Tessman, 2011; Winther 2012).  The antimicrobial 
concentration can also be overestimated in drugs that accumulate intracellularly (Giguère and 
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Tessman, 2011; Winther 2012).  The use of antimicrobial concentrations from tissue 
homogenates to predict efficacy is misleading and is not recommended (Giguère and Tessman, 
2011; Winther, 2012).   
 Nasal and bronchial secretions can be used to measure antimicrobial concentrations in 
respiratory secretions.  However, the secretions obtained, especially nasal secretions, may not 
accurately represent the target site of the infection especially when it is in the lower respiratory 
tract (Giguère and Tessman, 2012).  In human medicine, antimicrobial delivery to the respiratory 
tract is usually monitored by collecting bronchial secretions or sputum because it is much less 
invasive than bronchial biopsies.  The bronchial secretions and sputum are thought to provide an 
approximation of local mucosal concentrations of the antimicrobial (Pennington, 1981).  It was 
found that the correlation between antimicrobial serum concentration and bronchial secretions or 
sputum was variable (Pennington, 1981).  Measurement of antimicrobial concentrations in 
secretions can have some of the same issues as with tissue homogenates, especially with 
intracellular antimicrobials and potentially overestimating the antimicrobial concentration 
(Giguère and Tessman, 2011).   
 Microdialysis is a more recent technique that allows real time continuous monitoring of 
unbound or free antimicrobial concentrations directly in the extracellular fluid of the tissue of 
interest using a minimally invasive dialysis probe (Giguère and Tessman, 2011; Winther, 2012).  
Advantages are that long-term continuous monitoring can occur in secluded sites such as inside 
vessel, tissue, and bone, and it causes relatively minor tissue trauma (Winther, 2012).  The main 
disadvantages are the need to perform a thoracotomy to insert the probe. In addition, this 
technique cannot measure lipophilic drugs or intracellular concentrations of antimicrobials 
(Giguère and Tessman, 2011).  Microdialysis has been performed experimentally on pulmonary 
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tissue in anaesthetized humans and laboratory animals.  In horses, microdialysis has been 
performed on muscle tissue, placenta, and hoof lamellar tissue but not on pulmonary tissue 
(Winther, 2012). 
Absorbent disc or cotton swabs have been used to sample bronchial secretions and PELF 
in large animals (Winther, 2012).  A guarded swab is passed through the nares or mouth and 
trachea into the bronchus where the swab is then used to absorb the PELF (Foster, Martin and 
Papich, 2016).  This sampling technique retrieves a very small amount of undiluted PELF 
secretion for analysis.  The very small amount may restrict how much analysis may be performed 
on one sample.  Also, repeated sampling may increase inflammation in the lower airways which 
may increase inflammatory exudate which may influence an influx of drug into the secretion 
(Winther, 2012).  This technique is a relatively simple procedure to collect undiluted PELF 
samples, repeatable and does not require specialized equipment or a dilution method calculation 
(Winther, 2012; Foster, Martin and Papich, 2016).   
  Bronchoalveolar lavage allows for measurement of antimicrobial concentration in PELF 
and BAL cells.  The antimicrobial measured in the PELF represents the portion of the 
antimicrobial that diffuses across the blood-alveolar barrier (Giguère and Tessman, 2012).  
Bronchoalveolar lavages are a standard procedure used in equine medicine for diagnostic 
procedures mainly to evaluate cytology and microbiology in the equine lower respiratory tract 
(Winther, 2012).Bronchoalveolar lavages are relatively simple to perform in the standing sedated 
horse and require little equipment.  An endoscope or tubing such as an equine BAL catheter are 
passed through the nares, down the trachea, past the carina, and wedged in a terminal pulmonary 
bronchus.  Sterile isotonic fluid is infused rapidly into the lung and subsequently aspirated 
(Pusterla, Watson and Wilson, 2006).  Advantages of this technique are that it is a simple and 
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repeatable procedure and is relatively non-invasive causing little iatrogenic damage (Winther, 
2012).  The disadvantages are the quantity of PELF aspirated from BAL fluid can be small and 
variable and an endogenous dilution factor must be used to accurately correct for the amount of 
dilution in the aspirated BAL fluid (Winther, 2012).  The urea dilution method is commonly used 
to calculate PELF concentrations.  
Urea dilution method 
Urea can be used as an endogenous marker of PELF because it is small in size and 
relatively non-polar, allowing it to travel freely and easily across membranes (Giguère and 
Tessman, 2011; Rennard et al., 1985; Mills and Litser, 2005; Kirschvink et al., 2001; van de 
Graaf et al., 1991; Rennard et al., 1986; McGorum et al., 1993).  The assumption is that the urea 
concentration in the PELF should be equal to the urea concentration in the plasma because of 
complete diffusion (Giguère and Tessman, 2011; Kirschvink et al., 2001; van de Graaf et al., 
1991; Rennard et al., 1986; McGorum et al., 1993). Therefore, the volume of PELF can be 
adjusted for the dilution with saline by a simple mathematical equation and then the 
concentration of the drug in the PELF can be calculated.  
The concentration of urea in the BAL fluid and plasma can be used to calculate the volume of 
PELF (VolPELF) as follows: 
VolPELF = VolBAL x (UreaBAL / UreaPlasma) 
VolBAL represents the volume of BAL measured at the time of collection and UreaBAL and 
UreaPlasma represent the concentration of urea in BAL fluid and plasma, respectively. 
Once the volume of PELF is known, concentrations of the drug within PELF (DrugPELF) can be 
calculated as follows: 
 DrugPELF = DrugBAL x (VolumeBAL / VolumePELF) 
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DrugBAL represents the concentration of drug measured in BAL fluid. 
A study estimating the volume of PELF recovered by lavage using urea as a marker of dilution 
concluded that the volume of recovered PELF could be easily quantified with reasonable 
accuracy (Rennard et al., 1985).  A study performed in cats found the estimation of PELF 
fraction in lavage fluid using standardized lavage technique and correction for urea dilution 
resulted in a more accurate measure of cellular and non-cellular components in PELF (Mills and 
Lister, 2005).  Even though Mills and Lister (2005) were not investigating drug concentrations in 
PELF they concluded that in measuring cellular components in the PELF, the urea dilution 
method resulted in more accurate measurements.  Other studies have compared urea with other 
markers such as albumin and inulin (McGorum et al., 1993; Kirschvink et al., 2001).  McGorum 
et al. (1993) evaluated urea and albumin as endogenous markers of dilution of equine BAL and 
concluded that both techniques proved satisfactory and were of equal accuracy.  Albumin is a 
larger molecule and has reduced permeability compared to urea and therefore the urea dilution 
technique is considered superior for determining the concentration of PELF in BAL samples 
(McGorum et al., 1993).  Inulin is an exogenous marker and has been studied as exogenous 
markers of BAL fluid dilution.  An ideal external marker for BAL fluid dilution should be an 
inert marker for which the only source of the marker is the instilled lavage fluid. Additionally, 
the marker should not be metabolized by cells or cross the pulmonary epithelium, and can mix 
completely with the PELF in the lavaged lung segment (Kirschvink et al., 2001).  A study 
performed in horses determined there was no difference in the inulin or urea method in healthy 
versus heaves-affected horses and that inulin did not present any major advantages over urea, but 
the combined use of both inulin and urea improved standardization of studies comparing PELF 
compounds (Kirschvink et al., 2001).     
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There is concern that an influx of urea from blood either by increased respiratory 
membrane permeability or increased dwell time of infused fluid during BAL may lead to 
overestimation of the amount of PELF in BAL fluid and thus result in an underestimation of the 
concentration of drugs, proteins and cells in the PELF (van de Graaf et al., 1991; Giguère et al., 
2011). A clinical study in humans determined that urea influx during lavage was increased in 
patients with a high respiratory membrane permeability and this led to a relative underestimation 
of solutes in PELF (van de Graaf, et al., 1991).  Respiratory membrane permeability may be 
increased with inflammation or infection.  Because urea passes rapidly from blood and tissue 
spaces into the instilled lavage fluid, the dwell time of fluid in the lungs during lavage should be 
minimal (Haslam and Baughman, 1999).  If the dwell time is over 1 minute, PELF volume is 
expected to be overestimated by 100 to 300% (Kiem and Schentag, 2008; Rennard et al., 1986).  
Potential blood contamination during the BAL can also artificially increase the urea 
concentration in the PELF which can decrease the calculation of the drug concentration in the 
PELF (Kiem and Schnetag, 2008).   
BAL vs bronchial swab 
Recently there has been increased research in determining if BAL sampling or bronchial 
swab sampling is more accurate at accessing antimicrobial pulmonary pharmacokinetics in 
animals.   The bronchial swab technique is advantageous over BAL sampling, because it allows 
for direct measurement of antimicrobial concentration without the need to correct for dilution 
and it can be repeated in the same animal without concern for the volume of fluid required for 
sampling (Foster, Martin and Papich, 2016).  Direct PELF sampling using a bronchial swab 
technique has also been described for large animals and offers the advantage of not requiring 
volume correction (Foster, Martin and Papich, 2016).  The bronchial swab technique measures 
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drug concentrations at the level of the trachea or bronchi and thus may not be directly 
comparable to BAL derived measurements which sample the lower airways and alveoli (Kiem 
and Schentag, 2008).  Many studies in humans and animals have employed the BAL technique to 
measure antimicrobial concentrations in the lower airways to predict antimicrobial action against 
pulmonary bacterial pathogens (Giguère and Tessman, 2011; Giguère et al., 2011; Tynan et al., 
2016; Kuti and Nicolau, 2015; Mzyk et al., 2016; Zeitlinger et al., 2016).  To the author’s 
knowledge a direct comparison between these methods has not been performed.  
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CHAPTER 2: PULMONARY DISPOSITION AND PHARMACOKINETICS OF 
MINOCYCLINE IN THE ADULT HORSE 
 
Introduction 
Bacterial pneumonia is an important cause of illness in the adult horse (Giguère, 2015).  
Owners can incur significant financial losses due to pneumonia especially in the competition or 
race horse for whom transport associated pneumonia is not uncommon (Austin, Foreman and 
Hungerford, 1995; Raidal, Bailey and Love, 1997).  Prompt and effective treatment carries a 
favorable prognosis for return to competition in uncomplicated pneumonia cases (Ainsworth et 
al., 2000; Seltzer and Byars, 1996).  
Oral antimicrobials are often the mainstay for the treatment of pneumonia in adult horses 
due to their relative ease of administration and often reduced financial burden to the owner. 
Broad-spectrum antimicrobials available for oral administration to adult horses are limited to 
chloramphenicol, potentiated sulfonamides (sulfadiazine or sulfamethoxazole, combined with 
trimethoprim), enrofloxacin, metronidazole, and doxycycline.  Doxycycline, while 
demonstrating good distribution to the lung and a broad-spectrum of activity against many 
common bacterial respiratory pathogens including Streptococcus species (Bryant et al., 2000), 
underwent a drug market shortage resulting in marked increases in pricing (AARP, 2016). 
Although the cost and availability of doxycycline has improved recently, there remains a clinical 
need for additional oral antimicrobial treatment options in adult horses.   
Minocycline, a tetracycline derivative, is a time dependent bacteriostatic antimicrobial 
and as such its efficacy is influenced by the duration of time the drug concentration remains 
above MIC. Minocycline is available off-label for oral administration to horses (Schnabel et al., 
2012), and represents an attractive addition to the antimicrobial options due to its broad-spectrum 
of antimicrobial activity and excellent tissue penetration (Agwuh and MacGowan, 2006; 
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Bishburg and Bishburg, 2009), relatively low cost, and potential anti-inflammatory properties 
(Sapadin and Fleischmajer, 2006).  Pharmacokinetic and pulmonary disposition data on 
minocycline in the adult horse is lacking and is important information in order to more 
accurately predict the efficacy of minocycline in treating bacterial pneumonia in the adult horse. 
 There have been limited studies performed with minocycline in the adult horse.  
Schnabel et al. (2012) demonstrated that in adult horses minocycline achieved concentrations in 
synovial and cerebrospinal fluid that were adequate to treat infections caused by susceptible 
(MIC <0.25 ug/ml) bacterial organisms after intragastric (IG) administration of 5 doses of 
minocycline (4 mg/kg) (Schnabel et al., 2012).  In a separate study, the administration of a single 
intravenous (IV) dose of minocycline (2.2 mg/kg) resulted in minocycline concentrations in lung 
tissue homogenates that exceeded plasma concentrations at two hours post drug administration 
(Nagata et al., 2010).  While these findings suggest drug distribution into the lung, tissue 
homogenate concentrations are often inaccurate as they do not allow for differentiation between 
free (active) drug and drug bound to biological material (Giguère and Tessman, 2011; Liu, 
Muller and Derendorf, 2002; Mouton et al., 2008).  Measurement of drug concentrations in the 
PELF and BAL cells is thought to provide superior information regarding intrapulmonary 
antimicrobial activity (Giguère and Tessman, 2011).  Measurement of antimicrobial 
concentrations in the PELF and BAL cells has been described in multiple species including adult 
horses and foals (Rennard et al., 1986; Kiem and Schentag, 2008; Conte et al., 1996).  
The objectives of this study were to determine the pharmacokinetics of minocycline after 
a single IV and single IG dose and to determine the pharmacokinetics and pulmonary disposition 
of minocycline after multiple IG doses in adult horses.  Our study hypotheses were that: 
minocycline would be present in the PELF and BAL cells at concentrations exceeding those in 
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plasma within 3 hours of IV or IG administration and achievable trough concentrations in the 
PELF and BAL cells after administration of IG minocycline would exceed a target concentration 
of 0.25 µg/mL. 
Material and methods 
Animals 
 Three non-pregnant mares and four geldings between 10 and 31 years of age (mean of 15 
years of age and a median of 13 years of age) and weighing between 438 and 622 kilograms 
(mean weight of 527 kilograms and median weight of 543 kilograms) were used in this study.  
Study inclusion was determined based on normal physical and rebreathing examinations, and a 
normal routine plasma biochemistry profilea performed prior to study onset.  Horses were housed 
in individual stalls for 24 hours prior to and for the duration of each experimental period and 
were maintained on pasture between experimental periods.  Horses were fed 2 flakes of mixed 
grass and alfalfa hay twice daily and had access to water ad libitum.  Horses were monitored for 
drug reactions by performing and assessing physical examinations every 12 hours during the 
study and for 48 hours after completion of the study.  This study was approved by the University 
of Illinois Institutional Animal Care and Use Committee (protocol No. #14261). 
Experimental design 
Study 1: Single dose IV or IG minocycline – Minocycline hydrochloride was 
administered IV once at a dose of 2.2 mg/kg or IG via nasogastric intubation once at a dose of 4 
mg/kg with a 7-day washout period between administrations in a randomized cross-over 
experimental design. Hay was provided the afternoon prior to drug administration according to 
the standard feeding schedule at the Veterinary Teaching Hospital and two hours after IV or IG 
drug administration the morning of the study. Twelve hours prior to IV or IG drug administration 
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horses were instrumented with a 14-gauge extended use over-the-needle IV catheterb placed 
aseptically in the upper third of the left jugular vein for the purpose of serial collection of whole 
blood.  For the purpose of IV drug administration, a second catheterb was placed in the right 
jugular vein as described above.  The right catheter was removed immediately after drug 
administration.  The left catheter was removed 24 hours after IV or IG drug administration.  
Whole blood samples were collected immediately prior to drug administration, time (T) 0, and at 
T = 0.08, 0.17, 0.25, 0.33, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours after drug 
administration.  BAL was performed at T = 2, 4, 8, and 24 hours after drug administration. 
Study 2: Multiple dose IG minocycline – Minocycline was administered IG via 
nasogastric intubation at a dose of 4 mg/kg every 12 hours for a total of 5 doses. Horses were 
maintained on a standard morning and afternoon feeding schedule with the morning feeding 
offered two hours after the morning drug administration and the afternoon feeding offered 
approximately four hours prior to the evening drug administration.  Whole blood samples were 
collected via direct venipuncture from the left jugular vein immediately prior to administration of 
the first dose, T = 0, and at T = 0.5, 1, 1.5, 2, 6, 12, 14, 24, 26, 36, 38, 48, 48.5, 49, 49.5, 50, 54, 
60, 72 and 96 hours after administration of the first dose of minocycline.  BAL was performed at 
T = 24, 36, 48, 54, 60, and 72 hours after administration of the first dose of minocycline.  Whole 
blood sample collection at T = 12, 24, 36, and 48 hours and BAL collection at T = 24, 36, and 48 
hours were performed immediately prior to drug administration and were defined as trough 
concentrations for the purpose of this study. 
Minocycline hydrochloride preparation and administration 
Intragastric drug: Minocycline hydrochloride powderc was suspended in 500 mL of water 
and administered via nasogastric intubation immediately after resuspension. The nasogastric tube 
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was flushed with 1500 mL of water following drug administration and the tube immediately 
removed. 
Intravenous drug:  Minocycline hydrochloride powder was dissolved in sterile waterd to a 
5 mg/mL solution under sterile conditions.  The solution was then filtered through a 25 mm 
syringe filter with a 0.2 micron Supor® membranee placed in light-protective sterile bottles and 
kept out of direct light until administration within 2 hours of preparation. Intravenous drug 
delivery was via dedicated IV catheter, extension set and syringes and was timed to occur over 5 
minutes.  Heart and respiratory rates were monitored every 1 minute during drug administration 
and every 2.5 minutes for 15 minutes post drug administration. 
Bronchoalveolar lavage procedure and sample processing  
Prior to the BAL, horses were sedated with 150 mg of xylazine hydrochloridef IV into the 
jugular vein opposite to that used for whole blood sample collection. BAL fluid was collected 
through the biopsy channel of a sterilized 3m endoscopeg to ensure sampling of the distal 
airways. BAL sample collection alternated between the right or left lung, the order of which was 
randomly assigned prior to the initial BAL.  Instillation of a dilute lidocaine solution (5 mL of 
2% lidocaine diluted in 20 mL of saline) was used in passing the endoscope into the trachea and 
past the level of the carina. Once the endoscope was wedged in the most distal bronchus, 300 mL 
of sterile isotonic salineh was infused in 60 mL aliquots through the endoscope biopsy channel 
followed by gentle aspiration into sterile 60 mL syringes immediately after infusion of the last 
aliquot. The total volume of fluid recovered and side of lung sampled (right or left) was recorded 
and the individual samples pooled for immediate sample processing. Upon collection BAL fluid 
was pooled, 5 mL reserved for determination of total nucleated cell count and the remainder 
immediately centrifuged (3504 rpm x 10 minutes at 4°C) for separation of BAL cells from BAL 
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supernatant containing the PELF. The cell pellet was washed with PBS and re-suspended in 500 
µL acetonitrile: 0.2% formic acid. BAL supernatant and cells were stored at -80°C until batch 
analysis at a later date. 
Whole blood collection and sample processing 
Whole blood collected by catheter aspiration or direct venipuncture was placed into Na-
heparin tubesi and centrifuged (3504 rpm x 10 minutes at 4°C) within 15 minutes of collection. 
Plasma was then aliquoted and frozen at -80⁰C until batch analysis at a later date.   
Minocycline analysis via liquid chromatography/mass spectrometry (LC/MS/MS) 
Plasma and BAL cell and supernatant samples were thawed immediately prior to 
preparation for LC/MS/MS analysis. For metabolite extraction of plasma samples, 50 µL of 
plasma was mixed with 70 µL of methanol and spiked with 2 µL of internal standard 
(demeclocyclinej; 13.8 µg/mL) and followed by vortexing and centrifugation. For metabolite 
extraction of supernatant, 50 µL of supernatant was mixed with 70 µL of methanol and spiked 
with 1 µL of internal standard and followed by vortexing. The liquid was then loaded into the 
sample vial for LC/MS/MS injection. For BAL cell samples, cell pellets were subject to 
controlled sonicationk at the following settings: 4°C, amplitude 95, 10 minutes process time, 
pulse-on time 30 seconds, pulse-off time 45 seconds. The cell extracts were subject to 
centrifugation (14,800 rpm x 10 minutes at 4°C). The supernatant was subject to rapid drying 
and then resuspended into 150 µL 80% methanol, spiked with internal standard, and vortexed. 
The liquid was then loaded into the sample vial for LC/MS/MS injection.  
LC-MS/MS analysis was performed according to standard laboratory procedures in the 
Metabolomics Laboratoryl using a hybrid triple Quadrupole-Linear Accelerator trap mass 
spectrometer designed for LC-MS/MS analysism,n  and specialized software for data acquisition 
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and analysiso. The LC separation was performed with the following specifications: column 4.6 x 
50mm, 5µm; mobile phase A 0.1% formic acid in water; mobile phase B 0.1% formic acid in 
acetonitrile; flow rate 0.35 mL/minute; linear gradient at 0-2 minute 100%A, 7-10.5 minute 
0%A, 11-15.5 minute 100%A, autosampler at 15°C, injection volume 15 µL. Mass spectra were 
acquired under positive electrospray ionization with the ion spray voltage at +5500 V. The 
source temperature was 450°C, the curtain gas, ion source gas 1 and ion source gas 2 were 32, 
50, and 65 psi, respectively. Multiple reaction monitoring was used for quantitation of 
minocycline (m/z 458.2 - >m/z 441.1) with demeclocycline as the internal standard (m/z 465.2 - 
> m/z 448.2). Aliquots of drug free equine plasma and BAL fluid and cell suspension were 
provided for construction of standard calibration curves prior to sample analysis. Extraction 
efficiency for minocycline and the internal standard, and within and between run accuracy and 
precision for minocycline detection in plasma and BAL supernatant and cell suspension were 
performed.  
Determination of minocycline concentration within the PELF and BAL cells 
The estimation of volume of PELF was performed via the urea dilution method as 
previously described (Sapadin and Fleischmajer, 2006; Liu, Muller and Derendorf, 2002). Urea 
concentrations within BAL fluid and time-matched plasma samples were measured by use of a 
commercially available quantitative colorimetric urea determination kitp.  The kit used the 
improved Jung method which utilizes a chromogenic reagent that forms a colored complex 
specifically with urea.  The intensity of the color, measured at 520 nm, is directly proportional to 
the urea concentration in the sample.  The concentration of urea in the BAL fluid and plasma was 
used to calculate the volume of PELF (VolPELF) as follows: 
VolPELF = VolBAL x (UreaBAL / UreaPlasma) 
  
- 37 - 
 
VolBAL represented the volume of BAL measured at collection and UreaBAL and UreaPlasma 
represented the concentration of urea in BAL fluid and plasma, respectively. 
Once the volume of PELF was known, concentrations of minocycline within PELF (MinoPELF) 
was calculated as follows: 
 MinoPELF = MinoBAL x (VolumeBAL / VolumePELF) 
MinoBAL represented the concentration of minocycline measured in BAL fluid by LC-MS/MS. 
Pharmacokinetic and statistical analysis 
For each horse, plasma minocycline concentration versus time data were analyzed based 
on non-compartmental pharmacokinetics using commercially available softwareq. Maximum 
plasma concentration (Cmax) and time to achieve maximum plasma concentration (Tmax) were 
obtained directly from the data. The rate constant of the terminal phase (λz) was determined by 
linear regression of the logarithmic plasma concentration versus time curve using a minimum of 
4 data points.  Half-life of the terminal phase (t½λz) was calculated as ln 2 divided by λz. The area 
under the concentration-time curve (AUC) and the area under the first moment of the 
concentration-time curve (AUMC) were calculated using the trapezoidal rule, with extrapolation 
to infinity using Cmin/λz, where Cmin is the plasma concentration at the last measurable time point.  
Mean residence time (MRT) was calculated as: AUMC/AUC.  Bioavailability was calculated as 
(AUCIG /AUCIV) x (DOSEIV/DOSEIG). Apparent volume of distribution based on the AUC 
(Vdarea) was calculated as: IV dose /AUC• λz, apparent volume of distribution at steady state 
(Vdss) was calculated as (IV dose/AUC)/(AUMC/AUC), and systemic clearance (CL) was 
calculated from: IV dose/AUC. 
Normality of the data and equality of variances was assessed using Shapiro-Wilk’s and 
Levene's tests, respectively.  A paired t test was used for comparisons of Cmax in PELF and BAL 
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cells after IG and IV minocycline administration and for comparison of AUC for determination 
of steady state. Comparison of Cmax between sampling sites (plasma, PELF, BAL cells) was done 
using a Friedman repeated measures ANOVA.  When necessary, multiple pairwise comparisons 
were done using the Student-Newman-Keuls method. Comparison of plasma and PELF 
minocycline trough concentrations were performed using a linear mixed-effects model with 
horse modeled as random effect and sample type, time and interaction between time and sample 
type modeled as fixed nominal effects. Model fit was assessed using Akaike information 
criterion values.  Significance was set at P < 0.05.   
Results 
Horses used for study 1 and study 2 were identical except for one gelding that was lost to 
the study for an unrelated reason after study 1 and was replaced with another gelding for study 2.  
All horses tolerated IV and IG minocycline administration and BAL procedures well for both 
study 1 and study 2 and adverse clinical signs were not noted during drug administration.  One 
horse developed a mild fever (103°Farenheit rectal temperature) at 36 hours into study 2. All 
other physical examination findings were within normal limits and a single dose of flunixin 
meglumine (1.1 mg/kg, IV) was administered to that horse.  The 36 hour BAL was not 
performed, but the 36 hour drug dose was administered. All subsequent physical examinations 
were normal through 96 hour post drug administration and the horse was included in the 
remainder of the study. 
Study 1  
Mean ± SD Cmax and oral bioavailability (F%), and median (range) Tmax after IG 
administration of minocycline were 1.584 ± 0.9 µg/mL, 48 ± 15%, and 1.0 (range 0.5-1.0) hours, 
respectively.  The plasma pharmacokinetic variables after IV or IG administration of 
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minocycline are summarized in Table 1. The mean plasma concentration-time curves for 
minocycline for IV and IG administration were constructed (Figure 3). Area under the plasma 
concentration time curves (AUC) were 14 ± 5.2 (IV) and 12 ± 5.1 (oral) µg • h/mL.  
Concentrations of minocycline detected in PELF and BAL cells after a single IV or IG 
dose are summarized in Table 2. Mean ± SD Cmax and median (range) Tmax in the PELF after IG 
and IV minocycline administration were 5.032 ± 1.26 µg/mL and 3 (range 2.0-4.0) hours, and 
8.65 ± 8.29 µg/mL and 2.0 (range 2.0-4.0) hours, respectively. Mean ± SD Cmax and median 
(range) Tmax in BAL cells after IG and IV minocycline administration were 0.006 ± 0.008 µg/mL 
and 2 (range 2.0-8.0) hours, and 0.007 ± 0.007 µg/mL and 6.0 (range 2.0-8.0) hours, 
respectively. Differences in Cmax between IG and IV minocycline were not statistically 
significant for the PELF (P=0.314) or BAL cells (P=0.799).  Cmax in the PELF was significantly 
greater than Cmax in plasma and BAL cells for both the IG and IV minocycline (P < 0.001 all). 
Cmax in BAL cells was significantly lower than Cmax in plasma and PELF for both IV and IG 
minocycline (P < 0.001 all). 
Study 2 
  Plasma pharmacokinetic parameters measured after the first and fifth IG dose of 
minocycline are summarized in Table 3. Mean (SEM) plasma minocycline concentrations while 
dosing to steady state are illustrated in Figure 4. The AUC0–∞ after administration of a single 4 
mg/kg dose (15.2 ± 5.5 µg•h/mL) was not significantly different (P = 0.613) from the AUC after 
the fifth dose, between 48 and 60 hours (13.9 ± 6.4 µg•h/mL), indicating that steady state was 
reached.  At steady state mean plasma Cmax was 2.3 ± 1.3 µg/mL, terminal half-life (t1/2) was 
11.8 ± 0.5 hours and Tmax was 1.3 (1.0-1.5) hours.   
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Minocycline was detected in PELF and BAL cells at all measured time points, but 
concentrations in the PELF were much higher than those measured in BAL cells, and changes in 
PELF or BAL cell concentrations were not noted while dosing to plasma steady state (Figure 5 & 
6). PELF, BAL cell, and time matched plasma pharmacokinetic variables measured after IG 
administration of five doses of minocycline are presented in Table 4. PELF Cmax of minocycline 
was greater when compared to both plasma and BAL cell Cmax, and BAL cell Cmax was lower 
when compared to both plasma and PELF Cmax (P < 0.05 all). Minocycline concentrations 
measured in PELF were significantly greater than plasma concentrations at all trough time points 
(P < 0.001; Figure 7).  Mean plasma trough concentrations were all > 0.55 µg/mL and for each 
horse, the minimum plasma trough concentrations were > 0.25 µg/mL.  Median PELF 
concentrations at all time points were > 2.0 µg/mL and for each horse, the minimum PELF 
concentrations were > 0.68 µg/mL (Figure 7). 
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Table 1.  Plasma pharmacokinetic variables (mean ± SD unless otherwise specified) after 
intravenous (2.2 mg/kg) or intragastric (4.0 mg/kg) administration of minocycline to 6 adult 
horses.   
 
Variable Intravenous Intragastric 
λz (h-1) 0.067 ± 0.008 NA 
t½λz (h) 10.5 ± 1.3 NA 
Cinitial (µg/mL) 3.862 ± 1.378 NA 
Vdarea (L/kg) 2.73 ± 1.24 NA 
Vdss (L/kg) 2.16 ± 0.84 NA 
CL (ml/h/kg) 176.2 ± 65.2 NA 
AUC0–24h (µg • h/mL) 13.5 ± 5.0 10.8 ± 4.0 
AUC0–∞ (µg • h/mL) 14.0 ± 5.2 11.9 ± 5.1 
AUMC0–∞ (µg • h2/mL) 170.3 ± 60.6 NA 
MRT (h) 12.2 ± 0.9 NA 
C12h (µg/mL) 0.294 ± 0.197 0.248 ± 0.073 
Cmax (µg/mL) NA  1.584 ± 0.899 
Tmax (h)* NA 1.0 (0.5 – 1.0) 
F (%) NA 48.2 ± 15.2 
*Median and range; NA = not applicable 
λz = rate constant of the terminal phase. t½λz = half-life of the terminal phase. Cinitial = Initial 
measured plasma concentration (at 5 min). Vdarea = Apparent volume of distribution based on 
AUC. Vdss = Apparent volume of distribution at steady state. CL = Systemic clearance. AUC0–24h 
= Area under the plasma concentration versus time curve from time 0 to 24 h. AUC0–∞ = Area 
under the plasma concentration versus time curve extrapolated to infinity. AUMC0–∞ = Area 
under the first moment of the concentration versus time curve extrapolated to infinity. MRT = 
Mean residence time. Cmax = Maximum plasma concentration (observed) after the first dose. Tmax 
= Time to maximum plasma concentration (observed) after the first dose. C12h = Plasma 
concentration 12 h after administration of the first dose. F = Oral bioavailability. 
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Table 2.  Mean ± SD PELF and BAL cells minocycline concentrations (µg/mL) after IV (2.2 
mg/kg) or IG (4.0 mg/kg) administration of minocycline to 6 adult horses. 
 
 PELF BAL cells 
TIME (h) IV IG IV IG 
2 8.53 ± 8.4 4.48 ± 1.6 0.005 ± 0.007 0.005 ± 0.008 
4 3.31 ± 1.3 3.96 ± 1.4 0.003 ± 0.005 0.003 ± 0.003 
8  2.29 ± 1.9 1.21 ± 0.71 0.003 ± 0.002 0.001 ± 0.001 
24 0.7 ± 0.4 0.72 ± 0.5 0.001 ± 0.001 0.001 ± 0.001 
IV = intravenous; IG = intragastric 
 
 
Table 3.  Plasma pharmacokinetic variables (mean ± SD unless otherwise specified) after IG (4.0 
mg/kg) administration of a single dose of minocycline (1st dose) and at steady state (after 5th 
dose) in 6 adult horses.   
 
Variable (units) 1st Dose 5th Dose 
Cmax (µg/mL) 1.73 ± 1.05 2.33 ± 1.27 
Tmax (h)* 1.0 (1.0 – 1.5) 49.3 (49.0 – 49.5) 
AUC0–∞ (µg•h/mL) 15.2 ± 5.5 13.9 ± 6.4 
AUC0-t (µg•h/mL) 9.11 ± 3.84 38.55 ± 15.74 
t½λz (h) NA 11.8 ± 0.53 
*Median and range; NA = not applicable 
 
 
Table 4 – Median (25th and 75th percentiles) plasma, PELF, and BAL cells pharmacokinetic 
variables for minocycline after oral administration of 5 doses at 4 mg/kg of body weight q 12 h 
to 6 adult horses. 
 
Variable Plasma* PELF BAL cells 
Cmax (µg/mL) 0.98 (0.62 – 1.14)a 5.23 (2.99 – 17.60)b 
0.007 (0.004 – 
0.017)c 
Tmax (h) 6.0 (6.0 – 6.0) 9.0 (4.5 – 12.0) 3.0 (0 – 6.0) 
AUC48-96h (µg · h/mL) 
15.40 (9.73 – 
17.70)a 
66.34 (42.46 – 
220.66)b 
0.067 (0.031 – 
0.182)c 
*Only plasma samples obtained at the time of BAL collection were considered for calculation of 
Tmax, Cmax and AUC 
a,b,c Different letters within a given row indicate statistically significant (P < 0.05) differences 
between fluids with Friedman’s repeated measures analysis on ranks.  When necessary, multiple 
pairwise comparisons were done using the Student-Newman-Keuls method. 
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Figure 3: Concentration vs time curve after single dose oral (4 mg/kg) and IV (2 mg/kg) 
minocycline. Area under the plasma concentration time curves (AUC) were 14 ± 5.2 (IV) and 12 
± 5.1 (oral) µg • h/mL. 
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Figure 4: Mean (SEM) plasma minocycline concentrations while dosing to steady state. Time   
points circled in blue represent trough concentrations obtained immediately prior to drug 
administration 
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Figure 5: Median, IQR and min-max minocycline concentrations in PELF measured prior to 
drug administration (24, 36, 48 h) and at 6, 12 and 24 h after final minocycline dose. 
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Figure 6: Median, IQR and min-max minocycline concentrations in BAL cells (b) measured 
prior to drug administration (24, 36, 48 h) and at 6, 12 and 24 h after final minocycline dose. 
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Figure 7: Mean plasma and median PELF minocycline trough concentrations. Bars represent 
minimum and maximum concentrations. Stars denote significant differences between PELF and 
plasma (P<0.001). The dashed line is placed at 0.25 µg/mL. 
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Discussion 
In the present report, oral bioavailability (48%) varied considerably among adult horses 
(35 – 75%). While minocycline was detected in the PELF and BAL cells within 3 hours of IV or 
IG drug administration, only concentrations in the PELF exceeded those in plasma. As predicted, 
PELF trough concentrations exceeded the target concentration of 0.25 µg/mL at all measured 
time points. Contrary to our study hypothesis, minocycline BAL cell concentrations at all 
measured time points were well below concentrations detected in plasma and PELF and the 0.25 
µg/mL target concentration.   
The reported oral bioavailability of minocycline varies considerably across species 
(Maalnad, Guardabassi and Papich, 2014; Savin and Houin, 1988; Tynan et al., 2916).  Schnabel 
et al. (2012) estimated the oral bioavailability of minocycline at 23% in non-fasted adult horses 
although IV minocycline administration was not performed.  Recently, Giguère et al (2016) 
determined oral bioavailability of minocycline to be 32.0 + 18.0% in adult horses and 57.8 + 
19.3% in foals (Giguère et al., 2016). In study 1 of this report, bioavailability was greater than 
reported for adult horses in both previous studies and greatly exceeded estimates of 
bioavailability of oral doxycycline reported in adult horses (Bryant et al., 2000; Savin and Houin, 
1988; Womble, Giguère and Lee, 2007). In this study and those of Giguère et al. (2016) and 
Schnabel et al. (2011), minocycline was administered as a single 4 mg/kg dose via nasogastric 
intubation, but it is not known whether differences in feeding schedules between this study (hay 
twice daily) and the other studies (hay ad libitum) may have influenced drug absorption and thus 
measurement of bioavailability.  In study 1, oral bioavailability was determined to be 48% but 
with considerable variation among adult horses (35 – 75%).  Figure 8 illustrates the plasma 
minocycline concentration time curve for each horse in study 1 and shows the variability 
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between individual horses.  Horse 1 which had the lowest minocycline plasma concentrations 
was also the oldest horse in the study at age 31 years old.  We did not investigate the effect horse 
age might have on oral absorption of minocycline, but that would be something to determine in 
the future.    
Feeding can decrease oral bioavailability for a variety of drugs (Gu et al., 2007; Sykes et 
al., 2015; Davis, Salmon and Papich, 2006; Hnot et al., 2015).  While the impact of feeding on 
minocycline bioavailability has not been investigated in adult horses, significant reductions in 
Cmax of minocycline have been identified in fed versus fasted dogs (Hnot et al., 2015) and Cmax 
of doxycycline was significantly reduced in horses when the drug was administered concurrently 
with feed as opposed to 2 hours after feeding (Davis, Salmon and Papich, 2006).  During study 2 
of this report, horses were fed twice daily according to the standard Veterinary Teaching 
Hospital feeding schedule. Due to time constraints associated with BAL sample collection, 
horses were fed two hours after the morning drug administration and three to four hours prior to 
the evening drug administration. Interestingly, minocycline plasma concentrations measured two 
hours after morning drug administration were consistently higher than those measured two hours 
after evening drug administration, a result which suggests that feeding may have impacted drug 
bioavailability.  Figure 9 illustrates the difference in plasma concentrations after morning drug 
administration as compared to the evening drug administration in Study 2. Plasma drug 
concentrations were significantly greater after the morning administration (P < 0.05). Horses in 
study 2 were fed twice daily according to a standard feeding schedule and therefore drug 
administration in the morning occurred approximately 14 hours after feeding while drug 
administration in the evening occurred approximately 5 hours after feeding. This suggested that 
feeding may impact minocycline absorption. We performed a separate study with the objective to 
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compare the pharmacokinetics of minocycline after administration of a single oral dose in horses 
with feed withheld and with feed provided at the time of drug administration. Six healthy adult 
horses were administered intravenous (2.2 mg/kg) and oral minocycline (4 mg/kg) with access to 
hay at the time of oral drug administration (fed) and with access to hay delayed for 2 hours after 
oral drug administration (fasted), with a 7-day washout between treatments.  Plasma 
concentration versus time data were analyzed based on non-compartmental pharmacokinetics 
(Figure 10).  Mean ± SD bioavailability (fasted: 38.6% ± 4.6; fed: 15.7% ± 2.3) and Cmax (fasted: 
1.343 ± 0.418 µg/mL; fed: 0.281 ± 0.157 µg/mL) were greater in fasted horses compared to fed 
horses (P < 0.05 both). Median (range) Tmax (h) in fasted horses was 2.0 (1.5 – 3.5) and in fed 
horses was 5.0 (1.0 – 8.0), and was not significantly different between groups (Table 5).  
Delaying feeding hay 2 hours after oral minocycline administration improves drug 
bioavailability and thus plasma concentrations.  This feeding study determined feeding did have 
an effect on the oral bioavailability of minocycline in the adult horse.  
Another concern we had was the possible effect sedation might have on drug absorption.  
Each time a BAL was performed, the horse was sedated with 150 mg of xylazine to help restrain 
the horse for the procedure.  Sutton et al. (2012) investigated the effects of xylazine, detomidine, 
acepromazine, and butorphanol on equine solid phase gastric emptying and concluded that in 
cases presenting with nasogastric reflux or gastric impaction, low doses of xylazine would be 
recommended to facilitate diagnostic procedures and did not significantly affect gastric emptying 
in the horse.  Another study did find that xylazine produced a significant delay in gastric 
emptying, but the influence was transient and unlikely to be of clinical significance in healthy 
ponies (Doherty et al., 1999).   We were concerned there could be an effect on minocycline 
absorption and plasma concentration due to the xylazine administration so we performed a 
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randomized cross over study with 2 horses and administered oral minocycline (4 mg/kg) via 
nasogastric intubation with 150 mg of xylazine intravenous administration and without sedation 
with a 7-day washout period between treatments.  We found no difference in minocycline plasma 
concentrations between the sedated and unsedated horses with a p value greater than 0.05.   
In study 1 and study 2 reported here, PELF minocycline concentrations exceeded plasma 
concentrations at all time points with a mean PELF Cmax that was 5 times plasma Cmax at steady 
state plasma concentration. Penetration into the PELF is influenced by drug lipophilicity and 
protein binding (Rodvold, George and Yoo, 2011). The lipophilic properties of group 2 
tetracyclines (minocycline and doxycycline) may explain the high minocycline concentrations in 
PELF in this study (Agwuh and MacGowan, 2006; Sapadin and Fleischmajer, 2006; Maaland et 
al., 2014) as well as similar findings reported for minocycline in foals (Giguère et al., 2016) and 
for doxycycline in adult horses and foals (Womble, Giguère and Lee, 2007; Davis, Salmon and 
Papich, 2006).   
Plasma protein binding influences a drug’s ability to penetrate tissue because only the 
unbound fraction is available to cross biologic membranes. The percentage of plasma protein 
binding of minocycline was not determined in this study but has been reported to be 
approximately 68% in adult horses (Nagata et al., 2010) which is similar to previously reported 
percentages in dogs and humans (Agwuh and MacGowan, 2006; Maaland et al., 2014) and lower 
than estimated protein binding of doxycycline (Womble, Giguère and Lee, 2007).  Binding to 
protein within the PELF can further influence the amount of active drug that is available (Kiem 
and Schentag, 2008) particularly during inflammatory conditions resulting in changes in protein 
within the PELF. Protein concentrations in PELF have been reported to be much lower than in 
the plasma in healthy humans and in humans with pulmonary disease (Rennard et al., 1986) and 
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in healthy adult horses the percent protein binding of doxycycline in the PELF was much lower 
than protein binding in the plasma (Rodvold, George and Yoo, 2011).  
Pulmonary pharmacokinetic analysis in this study was based on measurement of 
minocycline concentrations in the PELF and BAL cells using BAL accompanied by volume 
correction with the urea dilution method. The PELF represents secretions on the interior alveolar 
wall and within the small bronchi and is often a site where bacterial organisms reside (Rodvold, 
George and Yoo, 2011). Thus, measurement of drug concentrations in the PELF, and in alveolar 
cells, is thought to provide superior information on intrapulmonary antimicrobial activity when 
compared to measurement of plasma or tissue homogenate drug concentrations (Giguère and 
Tessman, 2011; Rodvold, George and Yoo, 2011; Winther, 2012).  
While BAL with urea dilution has been widely described in horses and other species 
(Winther et al., 2010b; Giguère  et al., 2016; Womble, Giguère and Lee, 2007; Rodvold, George 
and Yoo, 2011; Winther, 2012; Cox et al., 2010; Giguère et al., 2011),  potential limitations 
associated with urea dilution that may result in over- or under-estimation of active drug 
concentrations within the PELF include cell lysis during BAL collection, blood contamination, 
increased BAL fluid dwell time, and measurement of both protein bound and unbound drug 
(Giguère and Tessman, 2011; Kiem and Schentag, 2008; Villarino et al., 2013; Foster, Martin 
and Papich, 2016).  Standardization of the BAL technique, as done in this study, is believed to 
minimize some of these limitations (Kiem and Schentag, 2008).  Direct PELF sampling using a 
bronchial swab technique has also been described for large animals and offers the advantage of 
not requiring volume correction (Foster, Martin and Papich, 2016).  This technique measures 
drug concentrations at the level of the trachea or bronchi and thus may not be directly 
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comparable to BAL derived measurements which sample the lower airways and alveoli (Kiem 
and Schentag, 2008).     
Bronchoalveolar lavage in the standing sedated horse is a repeatable and relatively non-
invasive procedure that typically causes little iatrogenic damage (Tynan et al., 2016; Ensink et 
al., 1993; Tee et al., 2012).  The possibility exists that multiple BAL procedures within the same 
horse could influence PELF drug concentrations due to residual fluid remaining in the lung from 
a previous BAL or due to the  potential that multiple BAL procedures could cause inflammation 
within the lung. Tee et al. (2012) investigated the effects of serial BAL samples in healthy 
Standardbred horses and found that there was no significant change in neutrophil percentages in 
the BAL fluid at any collection point.  Visual evidence of residual fluid was not noted during the 
bronchoscopic-guided BAL procedures. Cytology on BAL samples did identify increases in cell 
count and neutrophils (Table 6) which suggests some degree of inflammation associated with the 
procedure.  Inflammation is thought to improve pulmonary drug absorption by facilitating drug 
transport into the PELF (Kiem and Schentag, 2008; Tynan et al., 2016).  Whether the degree of 
transient inflammation associated with the BAL procedure was sufficient to influence PELF 
minocycline concentrations measured in this study is unknown.   
In this study, minocycline Cmax in BAL cells represented only 0.4% of plasma Cmax and 
0.1% of PELF Cmax after single and multiple oral doses. This finding was surprising as higher 
intracellular concentrations were expected. High intracellular concentrations are reported for 
tetracyclines (Davis, Salmon and Papich, 2006; Gabler, 1991; Forsgren and Bellahsene, 1985) 
with cellular-to-intracellular concentration ratios in polymorphonuclear leukocytes of 13 and 17 
reported in humans (Forsgren and Bellahsene, 1985) and adult horses (Davis, Salmon and 
Papich, 2006), respectively. PELF and BAL cell minocycline concentrations reported by Giguère 
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et al (2016) for foals were similar to our study.  While it is possible that intracellular drug 
concentration in BAL cells is less than that of peripheral cells given that the drug must first 
penetrate into the lung, in foals administered doxycycline, drug concentrations achieved in BAL 
cells were similar to serum concentrations (Womble, Giguère and Lee, 2007). The exact reason 
for decreased minocycline concentrations in BAL cells in this study is unknown. Lysis of BAL 
cells during sample processing can result in loss of drug for analysis and it is possible that lysis 
may have occurred during preparation of the cell pellet for analysis.  If poor BAL cell 
minocycline activity truly exists, it would be less likely to be of a clinical concern in adult horses 
as bacterial pathogens typically associated with pneumonia are extracellular and would thus be 
susceptible to the high minocycline concentrations in the PELF. 
Tetracyclines are reported to have good antimicrobial activity against many 
Streptococcus species (Schnabel et al., 2012). In order to accurately predict the efficacy of an 
antimicrobial for the treatment of bacterial pneumonia, knowledge of specific MICs for common 
bacterial pathogens in relation to achievable PELF concentrations is important.  An MIC 
<0.25µg/mL is often used to predict efficacy of doxycycline and minocycline for the treatment of 
equine pneumonia and other bacterial infections (Sweeney et al., 1991) and was therefore chosen 
as the target drug concentration in the PELF and BAL cells for this study. Information on 
Streptococcus equi subspecies zooepidemicus MIC values for minocycline in horses is limited to 
two studies. MIC50 values for minocycline are reported to be between 0.06 µg/mL and 0.12 
µg/mL (Schnabel et al., 2012; Forsgren and Bellahsene, 1985) while MIC90 values for 
minocycline are reported to be between 0.12 µg/mL and 8 µg/mL respectively (Schnabel et al., 
2012; Ensink et al., 1993).  While geographic differences in antimicrobial susceptibility may 
exist between these studies, these results suggest that achievable minocycline concentrations in 
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the PELF would be sufficient to treat most Streptococcus equi subspecies zooepidemicus 
bacterial pneumonias.  
The results of this study suggest that while minocycline distributes into the PELF and 
BAL cells of healthy adult horses, only minocycline concentrations in PELF would be sufficient 
for the treatment of bacterial pneumonia. To better predict drug bioavailability and pulmonary 
disposition in clinical cases, evaluation of minocycline pulmonary pharmacokinetics in horses 
with pulmonary disease should be further investigated.     
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Figure 8: Plasma minocycline concentration versus time curve for each individual horse in study 
2.  Each color represents a different horse.  
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Figure 9: Minocycline plasma concentration versus time at “trough” meaning the plasma 
concentration prior to next minocycline administration and the plasma concentration 2 hours post 
minocycline administration. 
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Figure 10: Mean plasma minocycline concentrations (+ SD) after IV (2.2 mg/kg) or oral (4.0 
mg/kg) administration of minocycline to six adult horses.  Horses treated orally were either 
fasted overnight and fed hay 2 h after drug administration (Oral-fasted) or fed hay prior to drug 
administration (Oral-fed). 
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Table 5: Plasma pharmacokinetic variables (mean ± SD unless otherwise specified) after IV (2.2 
mg/kg) or oral (4.0 mg/kg) administration of minocycline to 6 adult horses.  Horses treated orally 
were either fasted overnight and fed hay 2 h after drug administration (fasted) or fed hay prior to 
drug administration (fed). 
 
Variable 
Intravenous 
Oral 
 Fasted Fed 
λz (h-1) 0.060 ± 0.009a 0.062 ± 0.008a 0.038 ± 0.012b 
t½λz (h) 11.8 ± 1.9a 11.3 ± 1.2a 20.0 ± 7.0b 
AUC0–24h (µg • h/mL) 22.2 ± 7.5 16.0 ± 4.5  5.3 ± 2.0† 
AUC0–∞ (µg • h/mL) 23.3 ± 7.7 17.0 ± 4.8 6.8 ± 2.7† 
MRT (h) 13.9 ± 1.6a 15.4 ± 4.5a  30.7 ± 11.0b 
Cmax (µg/mL) NA  1.343 ± 0.418 0.281 ± 0.157†  
Tmax (h)* NA 2.0 (1.5 – 3.5) 5.0 (1.0 – 8.0) 
F (%) NA 38.6 ± 4.6 15.7 ± 2.3† 
Vdarea (L/kg) 1.78 ± 0.75 NA NA 
CL (ml/h/kg) 104.4 ± 37.3 NA NA 
*Median and range; NA = not applicable 
λz = rate constant of the terminal phase. t½λz = half-life of the terminal phase. AUC0–24h = Area 
under the plasma concentration versus time curve from time 0 to 24 h. AUC0–∞ = Area under the 
plasma concentration versus time curve extrapolated to infinity. MRT = Mean residence time. 
Cmax = Maximum plasma concentration (observed) after the first dose. Tmax = Time to maximum 
plasma concentration (observed) after the first dose. F = Oral bioavailability. Vdarea = Apparent 
volume of distribution based on AUC. CL = Systemic clearance. 
a,b Different superscript letters within a row indicate statistically significantly differences 
between the 3 methods of administration (P < 0.05).  
†Indicates a statistically significant difference between fed and fasted (P < 0.05). 
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Table 6: Mean ± SD total white blood cell count (WBC) and percent cell differentials measured 
in BAL fluid in Study 1 and Study 2. Mac = macrophage; lymph = lymphocyte; neut = 
neutrophil; eos = eosinophil; mast = mast cell. 
 
STUDY 1 
Mean ± 
SD 
2h 4h 8h 24h 36h 48h 54h 60h 72h 
WBC 154 + 
95 
197 + 
97 
171 + 
54 
180 + 
50 
     
% Mac 37 + 4 37 + 
13 
37 + 
15 
32 + 9      
%lymph 54 + 7 53 + 
17 
53 + 
16 
49 + 7      
% neut 5 + 2 9 + 7 17 + 
24 
16 + 7      
% eos 0.3 + 
0.5 
0.1 + 
0.2 
0.2 + 
0.3 
0.3 + 
0.4 
     
% mast 3 + 4 3 + 4 3 + 2 3 + 3      
STUDY 2 
WBC    230 + 
94 
267 + 
86 
336 + 
150 
516 + 
548 
874 + 
1048 
493 + 
342 
% Mac    44 + 13 45 + 6 32 + 
17  
29 + 
10 
28 + 
15 
24 + 
9.4 
%lymph    47 + 13 47 + 
11 
43 + 
13 
48 + 
18 
37 + 
15 
38 + 
19 
% neut    8 + 5 6 + 5 23 + 
24 
21 + 
26 
35 + 
29 
37 + 
27 
% eos    0.1 + 
0.2 
0.1 + 
0.3 
0.1 + 
0.2 
0.2 + 
0.3 
0.2 + 
0.5 
0.1 + 
0.2 
% mast    2 + 1 1+ 0.6 2 + 0.6 1 + 2 0.7 + 
0.8 
1 + 1 
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CONCLUSION 
 
This study demonstrated that minocycline distributes into the PELF and BAL cells of 
healthy adult horses.  It was determined that only minocycline concentrations in PELF would be 
sufficient for the treatment of bacterial pneumonia in adult horses.   Most pathogens causing 
bacterial pneumonia in the adult horse are extracellular pathogens and therefore the 
concentrations achieved in the PELF in this study suggest that minocycline would be suitable for 
the treatment of bacterial pneumonia.  
 The effect of feeding on minocycline bioavailability was evaluated in a follow-up study 
performed after the results from the initial pulmonary pharmacokinetic study suggested that time 
of feeding prior to drug administration influenced minocycline plasma concentrations.  The 
results of the feeding study were presented in the discussion and demonstrate that feeding hay 
reduces oral bioavailability of minocycline in the adult horse and delaying feeding hay for 2 
hours after oral minocycline administration improves the drug bioavailability and thus plasma 
concentrations.   
 The possible effect of sedation on the bioavailability of minocycline was also briefly 
investigated in a small study population and concluded not to have a significant effect on 
minocycline plasma concentrations.  
 The bioavailability for minocycline in the adult horse calculated in study 1 was 
determined to be 48% but with considerable variation among adult horses (35 – 75%).  Previous 
research had estimated the oral bioavailability of minocycline at 23% in non-fasted adult horses 
(Schnabel et al., 2012) and 32.0 + 18.0% in adult horses and 57.8 + 19.3% in foals (Giguère et 
al., 2016). In study 1 of this report, bioavailability was greater than reported for adult horses in 
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both previous studies.  It is not known whether differences in feeding schedules between this 
study (hay twice daily) and the other studies (hay ad libitum) may have influenced drug 
absorption and thus measurement of bioavailability.  Interestingly, in the feeding study we 
performed we estimated minocycline bioavailability to be 38.6% ± 4.6 in fasted horses and 
15.7% ± 2.3 in fed horses.  The bioavailability estimated from the feeding study was more 
consistent with the bioavailability findings of the previous studies (Schnabel et al., 2012; 
Giguère et al., 2016).  Bioavailability is variable among study subjects which was shown in 
Figure 8 as well as the in the large range from study 1 and large standard deviation in Giguère et 
al. (2016) study.  
For the study, healthy adult horses were used.  As discussed in the literature review, 
inflammation associated with bacterial pneumonia may alter antimicrobial transport and action at 
the site of infection.  To better predict pulmonary disposition in clinical cases, minocycline 
pulmonary distribution in horses with pulmonary disease should be evaluated.     
Minocycline is an attractive antimicrobial option to treat bacterial pneumonia in the adult 
horse.  This study demonstrated the pharmacokinetics and pulmonary disposition in the adult 
horse.  Minocycline is an orally-administered antimicrobial twice daily and is reasonably 
affordable in the adult horse.  Based on the feeding study performed, we recommend withholding 
feed for 2 hours post minocycline administration for optimal minocycline plasma concentrations. 
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FOOTNOTES 
 
a. Beckman Coulter AU680. Beckman Coulter Inc., Indianapolis, Indiana.  
b. Mila International, Inc., Erlanger, Kentucky.  
c. Fagron, Inc., St. Paul, Minnesota.  
d. Hospira, Inc., Lake Forest, Illinois. 
e. Pall Animal Health, Port Washington, New York. 
f. AnaSed® 100 injection manufactured by Lloyd, Shenandoah, Iowa.  
g. Olympus corporation of the America, Center Valley, Pennsylvania. 
h. Abbott Laboratories, North Chicago, Illinois.  
i. Covidien Ltd., Dublin Ireland. 
j. Sigma-Aldrich Corp, Atlanta, Georgia. 
k. QSonica LLC, Newton, Connecticut. 
l. University of Illinois Roy J. Carver Biotechnology Center, Urbana, Illinois. 
m. 5500 QTrap LC/MS/MS system, Sciex, Framingham Massachusetts.  
n. 1200 series HPLC system, Agilent Technologies, Santa Clara, California. 
o. Analyst 1.6.2 software. AB Sciex LP, Concord, Ontario, Canada.  
p. BioChain®urea assay kit Z5030016. Biochain Institute, Inc. Newark, California. 
q. PK Solutions 2.0, Summit Research Services, Montrose, Colorado. 
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